These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36191968)

  • 1. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with BRAF
    Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
    ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
    Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
    Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
    ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
    Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J
    Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
    Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T
    ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
    Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
    Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
    Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J
    ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
    J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
    Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
    Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
    Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
    Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
    Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
    Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Treatment Landscape in
    Tabernero J; Ros J; √Člez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
    Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
    Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
    van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
    Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Li S; Hu H; Ding D; Zhu Y; Huang J
    Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.